ConductScience.org, home

Paper41267972

Biology of PEST-containing nuclear proteins as potential targets in ovarian cancer (Review).

Liu H and 10 others. Oncol Lett, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Biology of PEST-containing nuclear proteins as potential targets in ovarian cancer (Review). Papers, record 41267972. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41267972

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Biology of PEST-containing nuclear proteins as potential targets in ovarian cancer (Review).
PubMed
Journal
Oncol Lett
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-11-23
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Liu HHao
2Jiang ZLZhi-Liang
3Liu YYi
4Zhu YHYong-Hao
5Akbar MUMuhammad Usman
6Khattak SSaadullah
7Lu ZZhendong
8Khawar MBMuhammad Babar
9Zhang YYue
10Saddozai UAKUmair Ali Khan
11Ji XYXin-Ying

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References176

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126596838Aspirin acetylates wild type and mutant p53 in colon cancer cells: identification of aspirin acetylated sites on recombinant p53.Tumour Biol2016https://conductscience.org/library/papers/26596838PubMed
235784636Carrier-free nanoprodrug for p53-mutated tumor therapy via concurrent delivery of zinc-manganese dual ions and ROS.Bioact Mater2023https://conductscience.org/library/papers/35784636PubMed
330640704Ovarian cancer: screening and future directions.Int J Gynecol Cancer2019https://conductscience.org/library/papers/30640704PubMed
415576594Beyond the ivory tower. The scientific consensus on climate change.Science2004https://conductscience.org/library/papers/15576594PubMed
521999765Overexpression of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression.Cancer Sci2012https://conductscience.org/library/papers/21999765PubMed
630892093Enhanced anti-proliferative and pro-apoptotic effects of metformin encapsulated PLGA-PEG nanoparticles on SKOV3 human ovarian carcinoma cells.Artif Cells Nanomed Biotechnol2019https://conductscience.org/library/papers/30892093PubMed
716174239Overexpression of cyclin D1 and c-Myc gene products in human primary epithelial ovarian cancer.Int J Gynecol Cancer2005https://conductscience.org/library/papers/16174239PubMed
820940128p53 at a glance.J Cell Sci2010https://conductscience.org/library/papers/20940128PubMed
929527331Targeting oncogenic Myc as a strategy for cancer treatment.Signal Transduct Target Ther2018https://conductscience.org/library/papers/29527331PubMed
1010468583The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.Proc Natl Acad Sci U S A1999https://conductscience.org/library/papers/10468583PubMed
1121496237Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties.J Exp Clin Cancer Res2011https://conductscience.org/library/papers/21496237PubMed
1217081971Wnt/beta-catenin signaling in development and disease.Cell2006https://conductscience.org/library/papers/17081971PubMed
1325285018Tumor heterogeneity in the recurrence of epithelial ovarian cancer demonstrated by polycomb group proteins.Onco Targets Ther2014https://conductscience.org/library/papers/25285018PubMed
1427308631MDM2/MDMX: Master negative regulators for p53 and RB.Mol Cell Oncol2016https://conductscience.org/library/papers/27308631PubMed
1521430439βTrCP regulates BMI1 protein turnover via ubiquitination and degradation.Cell Cycle2011https://conductscience.org/library/papers/21430439PubMed
1621270607Prognostic impact of p53, p27, and C-MYC on clinicopathological features and outcome in early-stage (FIGO I-II) epithelial ovarian cancer.Int J Gynecol Cancer2011https://conductscience.org/library/papers/21270607PubMed
1732741700Targeting p53 for the treatment of cancer.Semin Cancer Biol2022https://conductscience.org/library/papers/32741700PubMed
1821779514Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis.Genes Cancer2011https://conductscience.org/library/papers/21779514PubMed
1931477831UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-κB pathway.Oncogene2020https://conductscience.org/library/papers/31477831PubMed
2010521480The PEST domain of IkappaBalpha is necessary and sufficient for in vitro degradation by mu-calpain.J Biol Chem1999https://conductscience.org/library/papers/10521480PubMed

See all 176 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41267972

GET https://conductscience.org/api/papers/v1/41267972/references?page=2